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ABSTRACT
The ser-thr Akt plays a critical role in the regulation of cell survival, cell growth 
and proliferation, as well as energy metabolism and is dysregulated in many cancers. 
The regulation of Akt activity depends on the phosphorylation at two sites: (i) 
Thr308 in the activation loop by phosphoinositide-dependent kinase-1 (PDK1) and 
(ii) Ser473 hydrophobic motif at the carboxyl terminus by a second activity termed 
PDK2, which is the mTORC2 complex composed of mTOR, rictor, and Sin1. Previously 
we demonstrated that IKKα, a component of the IKK complex that controls NF-κB 
activation, participates in the Akt-dependent regulation of mTORC1. Here we have 
explored a potential involvement of IKKα in controlling Akt activity and whether this 
may involve mTORC2. The experiments show that IKKα associates with mTORC2 
in several cancer cells in a manner dependent on PI3K/Akt activity and that IKKα 
positively promotes Akt phosphorylation at Ser473 and at Thr308. Moreover, IKKα 
enhances mTORC2 kinase activity directed to Akt on Ser473 and Akt-mediated 
phosphorylation of FOXO3a and GSK3β, but not other Akt-associated targets such as 
TSC2 and PRAS40, indicating the existence of multiple mechanisms of Akt activation 
in cells. In addition, loss of IKKα suppresses growth factor-induced Akt activation 
associated with mTORC1 inhibition. These results indicate that IKKα serves as a 
feedforward regulator of mTORC2 and that IKKα could serve as a key therapeutic 
target to block mTORC2 and Akt activation in some cancers.
INTRODUCTION
Akt family proteins are an evolutionarily conserved 
group of serine-threonine kinases which phosphorylate 
key substrate involved in numerous cellular pathways [1, 
2]. The initiating step in Akt activation is the binding of 
PIP3 to the pleckstrin homology (PH) domain of Akt, and 
subsequent translocation of Akt to the plasma membrane, 
where it is activated by phosphorylation through PDK1 [1 
-3] and by PDK2 which has been shown to be the mTOR 
complex 2 (mTORC2) [4]. In cancers, Akt is often found 
constitutively activated downstream of growth factor 
receptor signaling, through activating mutations in PI3K, 
or following PTEN loss of expression or mutation [3, 5, 
6]. Activated Akt promotes cell survival, cell growth and 
proliferation, and energy metabolism in human cancers 
[3, 5]. Understanding the control of Akt is critical to 
provide insights into a variety of physiological and cancer-
associated mechanisms. 
The mammalian target of rapamycin (mTOR) 
is a conserved protein kinase that exists in two distinct 
complexes, mTORC1 and mTORC2 [2, 7]. mTORC1, 
which contains mTOR, Raptor and GβL, controls cell 
growth, at least partly, through its ability to phosphorylate 
S6K and 4EBP1, key regulators of mRNA translation [2, 
7, 8]. mTORC1 can be activated downstream of signaling 
induced by growth factors, such as IGF-1 and insulin, in a 
manner controlled downstream of PI3K/Akt [7, 8]. It has 
been shown that active Akt activates mTORC1 through 
phosphorylation of the tumor suppressor TSC2 to release 
TSC2 inhibition of the GTPase Rheb leading to positive 
regulation of mTORC1 [7 - 11]. Akt has also been shown 
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to phosphorylate PRAS40 to lead to mTORC1 activation 
[12, 13]. mTORC2, which contains mTOR, Rictor, Sin1 
and GβL, is rapamycin-insensitive and has been reported 
to regulate the actin cytoskeleton by modulating protein 
kinase C and Rho-family small GTPases [2, 4, 8]. As 
mentioned above, mTORC2 has also been shown to 
function as the PDK2 activity to phosphorylate Akt on 
ser473 [4]. Mechanisms for inducible control of mTORC2 
activity have been elusive, but it was shown recently 
that PIP3, generated downstream of PI3K, binds to Sin1 
to promote mTORC2 activity [14]. A separate study 
indicated that Sin1 acetylation is important for mTORC2 
activation [15]. 
The transcription factor nuclear factor kappa B 
(NF-κB) pathway is activated downstream of a variety of 
inflammatory mediators and growth factor pathways [16, 
17]. Cytokine and growth factor-induced activation of the 
IκB kinase (IKK) complex (IKK) is a key step involved in 
NF-κB activation leading to degradation of the inhibitor 
IκB and to the ability of NF-κB to accumulate in the 
nucleus and and initiate transcription of downstream target 
genes. The canonical NF-κB signaling pathway activates 
a heterodimer of a RelA-p50 complex and utilizes an 
IKK complex that is comprised of two catalytic subunits, 
IKKα and IKKβ, in association with a regulatory subunit 
IKKγ [16]. In the non-canonical signaling pathway, a 
dimer of IKKα promotes the activation of a p52-RelB 
heterodimer [16]. IKK and NF-κB activity are linked 
with cancer progression through the control of survival, 
cell proliferation, and angiogenesis [17-19]. We recently 
reported that IKKα associates with mTORC1 in PTEN-
deficient cancer cells in an Akt-dependent manner to 
regulate mTOR kinase activity directed to S6K and 4E-
BP1 [20-22]. In this pathway, IKKα phosphorylates 
mTOR in the mTORC1 complex to promote its kinase 
activity [23]. Reciprocally, Akt-induced association 
between mTOR/Raptor and IKK leads to the activation of 
NF-κB activity [22]. Recently it was reported that IKKα 
and IKKβ associate with the mTORC2 complex and that 
knockdown of either IKKα or IKKβ reduced Akt S473 
phosphorylation [24]. In the present study, we investigated 
the potential molecular link between IKK and mTORC2. 
We found that IKKα interacts with the mTORC2 complex 
in several cancer cells to control mTORC2 kinase activity 
directed to Akt Ser473. IKKβ was found not to be 
critical for this mechanism in a variety of cancer cells. 
Interestingly, PI3K/Akt signaling promotes an interaction 
between IKKα and mTORC2, driving mTORC2 activity. 
Loss of IKKα parallels loss of mTORC2 activity in 
affecting a subset of Akt-targeted substrates. The data 
indicate that IKKα functions in a feedforward pathway 
downstream of PI3K/Akt to promote mTORC2-mediated 
Akt activation.
RESULTS
Depletion of IKKα impairs Akt phosphorylation 
in mammalian cancer cells
Our previous studies demonstrated that IKKα plays 
an important role in mTORC1 activation downstream 
from Akt [20-23). Those results prompted us to investigate 
a potential involvement of IKKα in the regulation of 
Akt activity. To address this, we first performed RNAi 
experiment in two prostate cancer cell lines, PC3 and 
LNCaP, in which we previously demonstrated that IKKα 
has a positive function on mTORC1. It should be noted that 
PC3 cells do not express PTEN while LNCaP cells express 
a mutated form of PTEN. As shown in Figure 1A, siRNA 
specific for IKKα and IKKβ was effective at reducing 
the expression levels of these kinases. Subsequently, Akt 
activity was assayed using phosphospecific antibodies. 
The results revealed that knockdown of IKKα suppressed 
phosphorylation of Akt at both ser473 and thr308 (Figure 
1A), which are important phosphorylation residues 
required for full Akt activation. Additionally, as expected 
[20] the knockdown of IKKα in PC3 cells also blocked 
phosphorylation of S6K at thr389, a marker for mTORC1 
activity. There was no effect on the levels of endogenous 
Akt and S6K under these experimental conditions (Figure 
1A). Interestingly, knockdown of IKKβ displayed a 
minimal effect on phosphorylation of Akt and S6K, which 
contrasts with the findings of Xu et al [24]. These data 
indicated that IKKα positively modulates the activity of 
both mTORC1 and Akt in PTEN deficient prostate cancer 
cells (and see overall signaling pathways outlined in 
Figure 8). Next, we conducted RNAi experiment in both 
HeLa cells and DU145 prostate cancer cells, both of which 
are PTEN wild type, and found that knockdown of IKKα 
also markedly decreased phosphorylation of both Akt and 
S6K (Figure 1A). We then studied whether IKKα promotes 
Akt and mTOR activity in other mammalian cancer cell 
lines. We knocked down IKKα and IKKβ in A549, PANC1 
and MiaPaCa-2 cells and measured the activity of Akt 
and mTOR. The results indicate that the phosphorylation 
of both Akt and S6K was dramatically reduced after the 
knockdown of IKKα in these cells. IKKβ knockdown 
slightly decreases the phosphorylation of Akt and mTOR 
(Figure 1A). Identical results were obtained using distinct 
IKKα siRNA pools (Figure 1B). These results indicate that 
IKKα plays an important role in the activation of both Akt 
and mTORC1 independent of PTEN loss. 
Overexpression of IKKα induces Akt activation
In order to extend the results above, we asked if 
IKKα expression would induce Akt activity. We first 
transfected HA-tagged wild type IKKα into IKKα null 
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MEFs and measured phosphorylation of endogenous 
Akt. As shown in Figure 2A, transfection of IKKα leads 
to expression of IKKα, which was accompanied by an 
increase of phosphorylation of Akt at serine 473. To test if 
IKKα activates Akt in cancer cells, IKKα was transfected 
into PC3 cells and the phosphorylation of endogenous Akt 
was determined. The data demonstrate that expression 
of IKKα leads to an increase of phosphorylation of Akt 
(Figure 2B) similar to the data generated using IKKα null 
MEF cells. Next, we tested whether overexpression of 
IKKα induces phosphorylation of exogenously expressed 
Akt. HEK 293T cells were co-transfected as indicated 
with a Flag-tagged wild type IKKα and HA-tagged wild 
type Akt. Cells were lysed and immunoprecipitations of 
cellular lysates were performed with the anti-HA antibody. 
As shown in Figure 2C, IKKα expression increases 
exogenous Akt phosphorylation at both serine 473 and 
threonine 308. To determine whether IKKα promotes 
Akt kinase activity, we co-transfected IKKα with HA-
tagged Akt and then immunoprecipitated Akt from the 
Figure 1: Knockdown of IKKα decreases both Akt phosphorylation and mTORC1 activity. A. PC3, LNCaP, DU145, 
HeLa, A549, PANC-1 and MiaPaCa-2 cells were transfected with control siRNA, and siRNAs to IKKα and IKKβ as indicated. The cells 
were lysed 48 hrs after transfection and the levels of IKKα, IKKβ, and β-actin and endogenous phosphorylation of S6K and Akt were 
determined by immunoblotting with the indicated antibodies. The experiments were carried out on three separate occasions. B. PC3 cells 
were transfected with siRNA control, siRNA-IKKα-2, or siRNA-IKKα-3, and lysed 48 hrs after transfection. Levels of the indicated 
proteins or phospho-proteins were detected by antibodies used in Figure 1A. 
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cell lysates with the HA antibody, which was used for an 
in vitro Akt kinase assay against histone H2B, a classic 
Akt substrate. Our results indicate that overexpression of 
IKKα significantly increased Akt kinase activity (Figure 
2D). Overall, these results demonstrate that IKKα induces 
Akt phosphorylation and kinase activity.
IKKα-driven Akt activity does not affect Akt 
phosphorylation of TSC2 and PRAS40
Downstream of Akt signaling, IKKα positively 
regulates mTORC1 activity to modulate S6K and 4E-
BP1 phosphorylation [20-23]. It has been shown that Akt 
activates mTORC1 through inhibition of the TSC1/TSC2 
complex by TSC2 phosphorylation. Another recently 
reported intermediary for Akt activation of mTORC1 
is PRAS40 which normally inhibits mTORC1 but is 
inhibited by Akt through phosphorylation to promote 
mTORC1 activity. Here, we tested if IKKα-mediated 
Akt activation affects Akt-dependent phosphorylation 
of TSC2 and PRAS40, and therefore whether one effect 
of IKKα to promote mTORC1 is through the control of 
Akt. We knocked down IKKα in PC3 (PTEN null and 
high Akt Activity), PANC-1 (high Akt activity) and 
HeLa (lower Akt activity) cells and tested the effects 
on phosphorylation of Akt, TSC2 and PRAS40 as well 
as mTORC1 activity. Our results indicate that loss of 
IKKα leads to a decrease of Akt activity (Figure 3), as 
shown by loss of pAkt-S473, which is consistent with 
results shown in Figures 1 and 2. However, the reduction 
of phosphorylation of TSC2 and PRAS40 at published 
Akt sites is not observed with loss of IKKα while loss of 
mTORC1 is observed (loss of phosphorylation of S6K) 
as expected from our previous work [20]. We therefore 
conclude that IKKα-mediated mTORC1 activation is 
TSC2 and PRAS40-independent and that phosphorylation 
of Akt at S473 does not correlate with phosphorylation of 
PRAS40 and TSC2 (and see below for further discussion). 
Figure 2: Overexpression of IKKα increases phosphorylation and kinase activity of Akt. A. IKKα-/- MEF cells were 
transfected with different doses of IKKα as indicated, and the levels of phosphorylation of Akt, phospho-Akt, flag-IKKα and β-actin were 
measured by immunoblotting. B. PC3 cells were transfected with HA-IKKα and the levels of phosphorylation of Akt and levels of Akt, 
HA-IKKα and β-actin were detected. Results are representative out of at least 3 experimental repetitions. C. HEK293T cells were co-
transfected with HA-Akt-wild type and flag-IKKα-wild type as indicated, and the levels of phosphorylation of Akt, HA-Akt, flag-IKKα 
and β-actin were detected. Results are representative out of at least 3 experimental repetitions. D. Expression of IKKα enhances in vitro Akt 
kinase activity. HEK293T cells were co-transfected with different amounts of IKKα and with HA-Akt. The kinase activity of the HA-Akt 
immunoprecipitate to histone H2B was determined. The experiments were repeated three times.
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IKKα inhibition blocks stimulation of Akt activity 
induced by mTORC1 inhibition
It has been shown that mTORC1 and its downstream 
effecter S6K negatively regulate Akt activity through 
serine phosphorylation of insulin receptor substrate-1 
(IRS-1) [reviewed in 25]. Thus therapeutics that block 
mTORC1 have been shown to be less effective because of 
subsequent upregulation of Akt activity. We investigated 
if loss of IKKα affects IRS-1 phosphorylation and 
whether Akt would correspondingly be activated. We 
transfected different doses of siRNA IKKα into PC3 
cells to decrease endogenous IKKα expression levels 
and tested this effect on IRS-1 phosphorylation. Our 
data demonstrate that knockdown of IKKα significantly 
decreases phosphorylation of IRS-1 at both serine 636/639 
and serine 312 consistent with loss of mTORC1 and 
S6K activity (Figure 4A). Interestingly, loss of IKKα, 
while blocking mTORC1, repressed Akt activation. We 
compared the differences between loss of IKKα and 
Raptor, a key component of mTORC1, in their influence 
on phosphorylation of S6K, S6, IRS-1 and Akt. As shown 
in Figure 4B, siRNA to IKKα and to Raptor shows 
similar decreases of S6K, S6 and IRS-1 phosphorylation 
through mTORC1. However, knockdown of IKKα led to 
decreased Akt phosphorylation but knockdown of Raptor 
caused an increase in Akt phosphorylation, consistent with 
the known inhibitory action of mTORC1/S6K on IRS-1 
activity [25]. These data are consistent with a key role for 
IKKα in promoting Akt activation.
IKKα interacts with both mTORC1 and 
mTORC2 downstream of PI3K signaling
We previously reported that IKKα interacts with 
and activates mTORC1 [20] and data described above 
demonstrate that IKKα affects Akt phosphorylation. 
Given the critical role of the mTORC2 complex in 
activation of Akt, we thus determined whether IKKα 
also associates with the mTORC2 complex. To test this 
hypothesis, co-immunoprecipitation experiments were 
carried out in PC3 cells. First, cell lysates from PC3 cells 
were immunoprecipitated with the IKKα antibody and 
probed with antibodies for mTOR, Raptor and Rictor 
following gel electrophoresis. As shown in Figure 5A 
(left panel), immunoprecipitation with the IKKα antibody 
revealed robust association with mTOR, Raptor (part of 
the mTORC1 complex) and Rictor (part of the mTORC2 
complex). Similarly, immunoprecipitation with the mTOR 
antibody demonstrates mTOR association with IKKα, 
Raptor and Rictor (Figure 5A, middle panel). Importantly, 
immunoprecipitation with the Rictor antibody showed 
Rictor interaction with IKKα and mTOR (Figure 5A, right 
panel). These data demonstrate that IKKα is associated 
with both mTORC1 and mTORC2 in PC3 cells. Our 
previous size fractionation experiments [23] demonstrated 
that IKKα co-fractionates with mTORC1 in PC3 cells, so 
we conducted similar experiments to test whether IKKα 
Figure 3: IKKα-mediated Akt activity does not affect Akt-directed phosphorylation of TSC2 and PRAS40. PC3, PANC-
1 and HeLa cells were transfected with control siRNA or siRNAs to IKKα as indicated. The cells were lysed 48 hrs after transfection and 
the levels of IKKα and β-actin and endogenous phosphorylation of Akt, S6K, TSC2, and PRAS40 and were determined by immunoblotting 
with the indicated antibodies. 
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Figure 4: IKKα is required for activation of Akt downstream of mTORC1 inhibition. A. PC3 cells were transfected with 
different amounts of siRNA IKKα. The levels of endogenous phosphorylation of S6K, IRS-1, and Akt as well as levels of IKKα, mTOR and 
β-actin were determined by immunoblotting with the indicated antibodies. B. PC3 and HeLa cells were transfected with control siRNA or 
siRNA to IKKα and Raptor as indicated. The cells were lysed 48 hrs after transfection and the levels of IKKα, Akt, Raptor and β-actin and 
of endogenous phosphorylation of S6K, IRS-1 and Akt were determined by immunoblotting with the indicated antibodies. 
Figure 5: IKKα associates with both mTORC1 and mTORC2. Association with mTORC2 is dependent on PI3K and Akt. A. 
Immunoprecipitations of endogenous IKKα (left panel), mTOR (middle panel) or Rictor (right panel) prepared from PC3 cells lysates 
which were analyzed for IKKα, mTOR, Rictor or Raptor levels using indicated antibodies. Mouse (left panel) or rabbit (middle and right 
panels) IgG were used as negative control, and total cell lysate (1% input) indicates expression of mTOR complex proteins. B. and C. 
PC3 cell lysates were separated on a Superose 6 10/300 GL column. The indicated fraction numbers (fractionation 9-21) and their mTOR 
immunoprecipitates (fractionation 13-15) were analyzed by immunoblotting with the indicated antibodies. D. PC3 cells were treated with 
different doses of the PI3K inhibitor LY294002 for one hour, and the cell lysates were immunoprecipitated with Rictor or IKKα antibody, 
and association was determined by immunoblotting with the indicated antibodies. E. PC3 were treated with the Akt inhibitor Periforsine 
(KRX-0401) for one hour and the interaction between IKKα and the mTORC2 complex was measured as described in part D. 
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also co-fractionates with the mTORC2 complex. PC3 
cell extracts were analyzed by Superose 6 HPLC column 
chromatography, and column fractions 9 through 21 were 
analyzed by immunoblotting using antibodies for mTOR, 
Raptor, Rictor, and IKKα (Figure 5B). As shown in Figure 
5B, mTOR, Rictor and Raptor were found at the highest 
levels in fractions 14-16, with lower levels in fractions 
13 and 17. This pattern of size-dependent distribution of 
mTOR and Raptor is also very similar to that reported by 
Guan and colleagues [26]. IKKα was found at the highest 
levels in fractions 13-15. To determine whether IKKα 
and mTORC2 are associated in these column fractions, 
IKKα was immunoprecipitated from fractions 13-15 and 
the immunoprecipitate was analyzed by immunoblotting 
for IKKα, mTOR, Rictor and Raptor (Figure 5C). The 
results show that IKKα is associated with mTOR, Rictor 
and Raptor, with subunits at the highest levels in fraction 
14 and 15 and detectable association in fractions 13. 
Taken together, IKKα associates with both mTORC1 and 
mTORC2 complexes in PC3 cells. 
We previously showed that PI3 kinase (PI3K) 
induces IKKα-mTORC1 interaction to activate mTORC1 
[20-23] and it has been shown by others that mTORC2 
activates Akt downstream of PI3K [27]. Therefore, we 
examined if PI3K induces IKKα-mTORC2 interaction. 
PC3 cells were mock-treated or treated with different 
doses of a PI3K inhibitor, LY294002, for one hour and 
the endogenous IKKα-mTORC2 interaction was examined 
by co-IP (via association with Rictor). The results showed 
that LY294002 decreases the IKKα-Rictor interaction in 
a dose dependent manner (Figure 5D). To extend these 
studies, we determined if Akt activity is required for 
Figure 6: IKKα and Rictor have similar effects on regulation of phosphorylation of Akt and Akt substrates. PC3 cells 
were transfected with control siRNA or siRNA to IKKα or Rictor as indicated. The cells were lysed 48 hrs after transfection and the levels 
of IKKα, Rictor and β-actin and of endogenous phosphorylation of Akt, FOXO3a, GSK3β (specific band indicated by arrowhead) and S6K 
were determined by immunoblotting with the indicated antibodies. The experiments were performed three times and a representative blot 
is shown. 
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IKKα-mTORC2 interaction by using perifosine, an Akt 
inhibitor. Similar to the results generated with the PI3K 
inhibitor, treatment of PC3 cells with this compound 
blocked interaction between IKKα and mTORC2 (as 
measured with Rictor immunoprecipitation; Figure 5E). 
These data demonstrate that PI3K-Akt signaling promotes 
IKKα-mTORC2 interaction, functioning in a positive 
feedforward signaling pathway. 
IKKα induces Akt activity through mTORC2
It has been reported that Rictor and mLST8/GβL, 
both of which are essential components of mTORC2, 
are required for the hydrophobic motif phosphorylation 
of Akt/PKB and PKCα, but not S6K1. Moreover, in the 
mTORC2 complex, SIN1 and Rictor are required only 
for insulin-induced FOXO3, not for TSC2 or GSK3β 
phosphorylation following Akt activation [26, 27]. We 
thus knocked down both Rictor and IKKα in PC3 cells 
and compared their effects on phosphorylation of Akt, 
FOXO3a, GSK3β, and S6K. As shown in Figure 6, 
knockdown of Rictor leads to dramatic decreases of 
phosphorylation of Akt (both S473 and T308), FOXO3a, 
and a slight decrease of phosphorylation of GSK3β. 
However, the phosphorylation of TSC2-Serine 939 and 
S6K-T389, both of which are indicators of mTORC1 
activity, were unchanged. These results are in accordance 
with the published results by others indicating the 
involvement of Rictor with mTORC2 but not mTORC1. 
Consistent with these results, the knockdown of IKKα 
causes significant reduction of phosphorylation of Akt, 
FOXO3a, and a slight decrease of phosphorylation of 
GSK3β without any effect on TSC2 phosphorylation. 
These results indicate that IKKα loss and Rictor loss show 
similar results relative to control of mTORC2 activity and 
function. The difference is that knockdown of IKKα also 
decreases phosphorylation of S6K-T389, which matches 
our previous study that IKKα controls mTORC1 activity 
(Figure 6). These data demonstrated that IKKα positively 
regulates mTORC2 to Akt activation which is different 
from its regulation of mTORC1. 
IKKα increases mTORC2 kinase activity directed 
to Akt at serine 473 but does not affect mTORC2-
Rictor interaction
The results described above suggest that IKKα 
and mTORC2 function to regulate Akt activation in a 
similar manner, however it was important to determine if 
IKKα regulates mTORC2 kinase activity directed to Akt 
phosphorylation. We first tested if IKKα affects mTORC2 
kinase activity in vitro. mTOR was immunoprecipitated 
from PC3 from control cells or cells treated with siRNA 
to IKKα, and the ability of mTOR to phosphorylate 
recombinant Akt1 was analyzed. The data demonstrate 
that depletion of IKKα reduces mTOR kinase activity 
directed to Akt (Figure 7A). Xu et al found that inhibition 
of IKK reduced the association between Rictor and 
mTOR, however our studies found that knockdown of 
IKKα had no effect on the association between Rictor 
and mTOR (Figure 7A and 7B). We next expressed IKKα 
in increasing amounts followed by immunoprecipitation 
of mTOR or Rictor followed by in vitro kinase assays 
using recombinant Akt and anti-phospho S473. Both 
mTOR immunoprecipitation and Rictor precipitation 
showed dose-dependent enhancement of Akt S473 
phosphorylation following transfection of IKKα (Figure 
7C). In order to address whether kinase activity of IKKα 
is required to promote mTORC2 and the phosphorylation 
of Akt, we transfected HeLa cells with either wild-type 
or kinase-inactive IKKα and measured signaling related 
mTORC1 and mTORC2 activity. The results demonstrate 
(Figure 7D) that wild-type IKKα stimulates mTORC1 
(measured by S6K phosphorylation) and mTORC2 (as 
measured by the phosphorylation of Akt). However, 
kinase-inactive IKKα (KM) was not able to activate these 
pathways. Overall, these data demonstrate that IKKα, 
through its kinase activity, directly enhances mTORC2 
activity directed to phosphorylation of Akt (see model in 
Figure 8). 
DISCUSSION
Akt and mTOR regulation are intricately linked, 
with Akt functioning upstream of mTORC1 and 
mTORC2 regulating Akt activation. mTOR exists in two 
different complexes, mTORC1 and mTORC2. mTORC1 
phosphorylates S6K and 4EBP1 to control cell growth 
via translation, and other substrates for mTORC1 have 
been identified [2, 7]. Previous studies have demonstrated 
that Akt activates mTORC1 through the phosphorylation 
and subsequent inhibition of tuberous sclerosis complex 
2 (TSC2), promoting Rheb activation of mTORC1 [7-
11]. Furthermore, other publications have shown that 
Akt phosphorylates PRAS40, a negative regulator of 
mTORC1 to relieve its inhibitory function on mTORC1 
[12, 13]. We previously reported that IKKα is important 
for efficient activation of mTORC1 activity downstream 
of Akt-induced signaling [20-23]. In those studies, we 
found that IKKα interacts with and phosphorylates mTOR 
in the mTORC1 complex to activate mTORC1, and that 
Akt signaling drives the IKKα-mTORC1 interaction. 
Interestingly, the canonical IKK complex (IKKα, IKKβ, 
IKKγ) was recruited into the mTORC1 complex, yet IKKβ 
was found not to be involved in mTORC1 activation but 
was shown to be important for a reciprocal activation of 
NF-κB controlled by mTORC1 [23]. Another report found 
that IKKβ can phosphorylate TSC1 in response to TNF to 
promote mTORC1 activation [28], but our studies indicate 
that IKKα is the dominant form of IKK downstream of 
Akt signaling [21]. 
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Figure 7: IKKα enhances imTOR/Rictor kinase activity to Akt. A. PC3 cells were transfected with siRNA IKKα. Endogenous 
mTOR/Rictor was immunoprecipitated with the mTOR antibody for mTOR/Rictor kinase activity directed toward recombinant Akt. The 
phosphorylation of Akt (anti-phospho-S473) and total Akt, mTOR and Rictor in the kinase assay system and the amount of mTOR, Rictor 
and IKKα in the lysate were measured with the indicated antibodies. B. PC3 cells were transfected with different amounts of siRNA IKKα. 
The cells were lyses 48 hours post-transfection and the endogenous mTOR/Rictor was immunoprecipitated with the TOR antibody and 
incubated with recombinant Akt. The level of mTOR and Rictor in the immunoprecipitates and of endogenous Akt, mTOR, and IKKα in 
lysates was determined with the indicated antibodies. C. HEK293T cells were transfected with different amounts of wild type HA-IKKα, 
and mTOR and Rictor were immunoprecipitated. mTOR/Rictor kinase activity toward recombinant Akt was determined with phospho-Akt 
antibody following in vitro kinase assay. The protein levels of Akt, mTOR and Rictor in the immunoprecipitates were determined with 
the indicated antibodies. D. HeLa cells were transfected with different amounts of wild type or kinase mutated GST-IKKα (expression 
indicated by arrow) and the phosphorylation of Akt and S6K, as well as expression of Akt, S6K and GST-IKKα was detected (upper panel). 
mTOR were immunoprecipitated and levels of mTOR and Rictor in the immunoprecipitate were examined (lower panel).
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In the current study, we show that IKKα associates 
with the mTORC2 complex and positively regulates 
mTORC2 kinase activity directed to Akt (Figure 8). Others 
[24] have suggested that IKKβ is important in this response 
and that IKK promotes Rictor association with mTOR 
in the mTORC2 complex, but our data (at least in the 
cancer cells studied) indicate that IKKα is more important 
than IKKβ in controlling Akt activation and that there 
is no reduction in Rictor-mTOR association following 
IKKα knockdown. Data from our studies indicate that 
PI3K and Akt drive IKKα onto the mTORC2 complex, 
promoting a feedforward process to maintain mTORC2 
activity. Previously we found that the IKKα-directed 
phosphorylation (S1415) of mTOR in the mTORC1 
complex stimulates mTORC1 kinase activity [23]. While 
expression of an S1415A mTOR mutant suppressed 
mTORC1 activity, it did not suppress phosphorylation of 
Akt [23], suggesting that phosphorylation at this site by 
IKKα does not regulate mTORC2 activity. Yet our data 
indicate that the kinase activity of IKKα is required to 
promote mTORC2 and Akt activation (Figure 7D). Thus 
a mechanism to explain the effect of IKKα on promoting 
mTORC2 activity is not known. Our findings provide 
insights into a previous report showing that the activation 
of Akt downstream of BAFF receptor signaling requires 
IKKα [29]. 
Knockout of Rictor in mice demonstrated that 
mTORC2 activates Akt (phosphorylation at S473 and 
T308) and controls certain, but not all, Akt substrates [27]. 
The animal study reported by Sabatini group demonstrated 
that both Rictor and mLST8 (GβL) are involved in 
mTORC2-induced phosphorylation of FOXO3a, but 
not TSC2 or GSK3β. In 2006, mSin1 was identified as 
another component of mTORC2 but not mTORC1 [26, 
30]. It has been demonstrated that mSin1 is necessary 
for the assembly of mTORC2 and for its capacity to 
phosphorylate Akt/PKB [26, 30]. In addition, similar to 
the function of Rictor to mTORC2, mSin1 mediates Akt 
phosphorylation of FOXO3a [30], while other Akt targets 
TSC2, GSK3, and the TORC1 effectors, S6K and 4E-BP1 
were unaffected. A mechanism to explain the selective 
phosphorylation of Akt substrates in these studies is 
not understood. Our data indicate that IKKα acts as an 
upstream regulator of mTORC2 to control mTORC2 
activity to Akt and its substrate FOXO3a, which is similar 
to the function of Rictor and Sin1 in regulating Akt and its 
downstream targets. Others have reported that IKK-related 
kinases IKKε and TBK1 can directly phosphorylate Akt at 
S473 [31, 32], thus our data indicate an additional pathway 
whereby IKK family members can drive Akt activation. 
Our observations that IKKα is critical for regulation of 
both mTORC1 and mTORC2, along with its established 
roles in the activation of NF-κB signaling, indicate IKKα 
as an important cancer therapeutic target. 
MATERIALS AND METHODS
Cell lines, cell culture and transfection
IKK wild-type and IKKα-/- were provided by I. 
Verma and M. Karin. The prostate cancer cell lines PC3, 
LNCaP and DU145, HEK293T, Hela, A549, PANC1 
and MiaPaCa-2 cell lines were from ATCC. The LNCaP 
cell line was cultured in PMRI1640 with 10% fetal 
bovine serum (FBS), 2 mM glutamine, and 100 U/ml 
penicillin and streptomycin (GIBCO). All other cells 
were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum 
(FBS), 2 mM glutamine, and 100 U/ml penicillin and 
streptomycin (GIBCO). Transfections were performed 
using Lipofectamine and Plus (Invitrogen) following 
the manufacturer’s instructions. In brief, 3-4 hours after 
transfection, cells were recovered in full serum for 36 
hours or in full serum for 24 hr and then serum-starved for 
16 to 24 hours as indicated. 
 Antibodies and reagents
Antibodies were obtained from the following 
sources. Antibodies against IKKα, IKKβ, and mTOR 
were obtained from Upstate Biotechnology. Raptor 
and Rictor antibodies were obtained from Bethyl 
Laboratories. Anti-HA and anti-Flag antibodies were 
obtained from Roche and Sigma, respectively. Anti-
Actin was obtained from Calbiochem. The anti-S6K and 
control rabbit IgG, as well as HRP-labeled anti-mouse 
and anti-rabbit secondary antibodies were from Santa 
Cruz Biotechnology. Recombinant Human inactive Akt 
is from Upstate Biotechnology. All other antibodies 
Figure 8: Model for IKKα regulation of mTORC1 
downstream of Akt (A) and regulation of mTORC2 
upstream of Akt (B). A. Shows the downstream effectors 
of Akt in regulating different key pathways. Akt promotes the 
interaction of IKKα with the mTORC1 to promote mTORC1 
activity. B. PI3K signaling via Akt promotes the interaction 
with the mTORC2 complex to promote Akt activity directed to 
a subset of substrates. 
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were from Cell Signaling. Other reagents were obtained 
from the following sources: Insulin was from Invitrogen 
Corporation. Protease and phosphatase inhibitor cocktails 
were from Roche. The CHAPS was from Pierce. Protein 
A and protein G agarose beads were from Invitrogen Life 
Technologies. 
RNA interference
siRNA SMARTpool IKKα (Catalog #M-003473) 
employed in all experiments except Figure 1B. Other two 
siRNA, labeled as siRNA-IKKα-2 and siRNA-IKKα-3 in 
Figure 1B are from Santa Cruz and Sigma, respectively. 
Raptor and Rictor were from Dharmacon. Each of these 
represents four pooled SMART selected siRNA duplexes 
that target the indicated gene. HeLa, PC3, LNCaP and 
DU145 cell lines cells were transfected with indicated 
SMARTpool siRNA or nonspecific control pool using 
DharmaFECT 1 reagent (Dharmacon) according to 
the manufacturer’s instructions. In brief, 20 nM final 
concentration of siRNA was used to transfect cells at 60%-
70% confluency. Twenty-four hours after transfection, 
cells were recovered in full serum or were serum-starved 
16 hr before harvest. Cells were harvested 48 to 72 hr after 
siRNA transfection.
Cell lysis, immunoblotting and 
coimmunoprecipitation
In brief, cells growing in 100 mm dishes were 
rinsed twice with cold PBS and then lysed on ice for 
20 min in 1 ml lysis buffer (40 mM Hepes pH 7.5, 120 
mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM 
glycerophosphate, 50 mM NaF, 0.5 mM orthovanadate, 
and EDTA-free protease inhibitors (Roche)) containing 
1% Triton X-100. After centrifugation at 13,000Xg for 
10 min, samples containing 20-50 μg of protein were 
resolved by SDS-PAGE and proteins transferred to Pure 
Nitrocellulose Membrane (Bio-Rad Lab.), blocked in 5% 
nonfat milk, and blotted with the indicated antibodies. 
For immunoprecipitation experiments, the lysis buffer 
contained 0.3% CHAPS instead of 1% Triton. 4 μg of the 
indicated antibodies were added to the cleared cellular 
lysates and incubated with rotation for 6-16 hours. Then 
25 μl of protein G agorose was added and the incubation 
continued for 1 h. Immunoprecipitates captured with 
protein G-agorose were washed three times with the 
CHAPS Lysis Buffer, two times by wash buffer A (50 
mM Hepes, PH 7.5, 150mM NaCl), and boiled in 4x SDS 
samples buffer for western blot. 
In vitro mTOR/Rictor kinase assay
We followed the protocol for the in vitro assay 
of Rictor/mTOR kinase acivity directed to Akt [4]. 
In brief, transfected HEK293T cells were grown in 
100mm dishes for 48 hours in DMEM containing 10% 
FBS, and lysed in 1ml lysis buffer with 0.3% CHAPS. 
Half of total cell lysate was incubated with anti-mTOR 
or anti-Rictor antibody for 3 hours, followed by another 
hour of incubation with 25 µl protein G agarose beads. 
Immunoprecipitates were washed four times by lysis 
buffer, once by the Rictor-mTOR kinase buffer (25 mM 
HEpes PH 7.5, 100 mM potassium acetate, 1 mM MgCl2). 
For kinase reaction immunoprecipitates were incubated in 
a final volume of 15 μl for 20 min at 37 °C in the rictor-
mTOR kinase buffer containing 500 ng inactive Akt1/
PKB1 (Akt1/PKB1, Upstate Biotechnology, #14-279) and 
500 μM ATP. The reaction was stopped by the addition of 
200 μl ice-cold Enzyme Dilution buffer (20 mM MOPS, 
pH 7.0, 1 mM EDTA, 0.01% Brij 35, 5% glycerol, 0.1 % 
2-mercaptoethanol, 1 mg/ml BSA). After a quick spin, the 
supernatant was removed from the protein G-sepharose 
and analyzed by immunoblotting.
Statistics
Data from the in vitro experiments are expressed 
as mean ± SEM from a minimum of 3 independent 
experiments. Comparison between groups were carried 
out by 2-way ANOVA or Student’s t test, and a P value of 
less than 0.05 was considered significant.
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